

## **Candidiasis Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)**

Market Report | 2023-01-23 | 115 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The candidiasis therapeutics market is expected to register a CAGR of 5.1% over the forecast period (2022-2027).

The COVID-19 pandemic impacted the studied market significantly. In the initial phase of the pandemic due to the lockdown and shutdowns, the global trade was affected drastically, and the supply chain was disrupted, which hampered the sales of candidiasis drugs and therapeutics. However, even though the market showed a decline in sales initially, the increasing number of infections during the pandemic phase increased the demand for candidiasis therapies. Fungal co-infections were found along with the Covid-19 infections. For instance, a study published in July 2020 "Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China" concluded that COVID-19 patients who are severely ill or immunocompromised had a higher chance of suffering from invasive mycoses. When the study was conducted in China by a group of researchers, Aspergillus and Candida infections in COVID-19 patients were found. Thus, the demand for innovative therapies increased for candidiasis infection during the pandemic. Therefore, even if Covid-19 had a slightly negative impact on the market initially, the market has seen steady growth during the pandemic, positively impacting the growth of the market studied.

Furthermore, the growing prevalence of candidiasis infection is further driving the demand for new therapeutics for treatment, augmenting the growth of the market. The global burden of candida infection is rising currently. For instance, among all the other countries globally Zimbabwe is one of the major countries affected by several healthcare challenges. Research published in June 2021 titled "Determining the burden of fungal infections in Zimbabwe" reported that the estimated prevalence of recurrent vulvovaginal candidiasis (RVVC) was 2,739/100,000 in Zimbabwe and the estimated burden is high in comparison to other African countries. These high prevalent cases of candidiasis in low-income countries like Zimbabwe and others are creating demand for the availability of better and advanced therapeutics which in turn is expected to impact the studied market growth.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Moreover, candidiasis in the mouth or Oral Candidiasis is one of the most common infections that affect the majority of the population globally. The persistent oral infection among the population requires treatment to combat the spread of the infection, which further boosts the studied market growth. An article updated in the National Library of Medicine in March 2022 titled "Oral Candidiasis" reported that Oral candidiasis can occur in immunocompetent or immunocompromised patients. But this is more common in immunocompromised hosts. This oral candidiasis occurs equally in males and females, while it typically occurs in neonates and infants. The global burden of candidiasis is growing with the rising population globally. Hence, the therapeutics for candidiasis have become more important. Therefore, the burden of oral candidiasis is expected to drive the market for candidiasis therapeutics in the future.

In addition, the growing awareness of candidiasis infection among the target population and product innovation in all segments in the market studied are driving the demand for new therapeutics. For instance, in January 2020, Astellas Pharma Inc. received approval from the United States Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for MYCAMINE (micafungin for injection) in support of the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age. In addition, in September 2021, Cidara Therapeutics, Inc. a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, presented new clinical and non-clinical data for its Rezafungin, in two poster presentations at the 10th Congress on Trends in Medical Mycology (TIMM) Webinar which took place in Aberdeen, Scotland. Rezafungin is a novel once-weekly echinocandin which is being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. Hence, product innovation is expected to boost market growth.

Therefore, owing to the aforementioned factors the studied market is predicted to see growth over the forecast period. However, narrow pipeline molecules and competition from herbal medicines and alternative therapies can hinder market growth.

#### Candidiasis Therapeutics Market Trends

##### Vulvovaginal Candidiasis Segment is Expected Dominate the Market

Vulvovaginal candidiasis (VVC) is a vaginal fungal infection confirmed to be caused by Candida species, and in most cases, it is caused by Candida albicans. The VVC can be caused by other Candida species or yeasts occasionally. VVC is also called the recurrent vulvovaginal candidiasis (RVVC) due to it being a relapsing vaginal fungal infection. The high prevalence of the infection among the population is driving the segment growth and thus the vulvovaginal candidiasis segment is predicted to see growth over the future.

Increasing research to find the prevalence of the VVC or RVVC is also expected to boost segment growth. The research article "Treating (Recurrent) Vulvovaginal Candidiasis with Medical-Grade Honey-Concepts and Practical Considerations" published in August 2021 shows that the prevalence varies owing to the age of the population and can be as high as 9%. Due to the lack of treatment options in 57% of the cases, relapses occur within six months after fluconazole maintenance therapy, which is the commonly used treatment among other options.

In addition, a research "Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis-United States" published in April 2022 reported that Vaginitis is a common complaint in the outpatient setting and Candida species cause approximately 30% of vaginitis episodes, with an estimated 75% of women affected by vulvovaginal candidiasis (VVC) during their lifetimes. Thus, the high prevalence of the infection among the target population, the vulvovaginal candidiasis segment requires more attention and therapeutics for treatment. Thereby, driving the growth of the segment.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Additionally, the research and development (R&D) in the segment are increasing. Major players are focusing on developing products for the vaginal yeast infection, which in turn is predicted to drive the segment growth. For instance, in February 2021, SCYNEXIS, Inc. a biotechnology company focused on developing therapies and drugs for fungal infections partnered with Amplify Health, one of the global leaders in contract commercialization organization, to launch Brexafemme (ibrexafungerp) in the United States. Brexafemme is the expected trade name for ibrexafungerp, an oral antifungal product candidate for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. In addition, In April 2022, Mycovia Pharmaceutical's new product VIVJOA (oteseconazole), the First and received Food and Drug Administration (FDA) approval and became the only FDA-approved medication for recurrent vulvovaginal candidiasis (RVVC) or chronic yeast infection. Thus, the increasing R&D in the segment is anticipated to drive the segment growth.

Therefore, such factors mentioned above are anticipated to drive the segment growth, which is expected to propel the overall market growth over the forecast period.

#### North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the market owing to the increasing target population in the countries across the region. The United States holds most of the shares in the region among other countries.

Increasing research and product development in the United States is expected to boost the market growth in the region. For instance, research was conducted which was aimed to calculate rates and evaluate diagnosis and treatment practices of Vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) in the United States. The study was conducted using IBM MarketScan which includes health insurance claims data on outpatient visits and prescriptions for >28 million people. The study results showed that among 12.3 million female patients in the IBM MarketScan database, 149,934 (1.2%) had a diagnosis code for VVC among those, 3.4% had RVVC. The VVC rate was highest in the South census region (14.3 per 1,000 female patients). Thus, the prevalence of vaginal candidiasis is generating demand for new therapeutics in the country, driving the studied market growth.

In addition, the major players are engaged in innovation and product development in the country which is garnering the market studied growth in the country. For instance, in September 2021, SCYNEXIS, Inc. announced the availability of BREXAFEMME (ibrexafungerp tablets) in the United States. BREXAFEMME is the first and only oral non-azole prescription medication approved by the Food and Drug Administration (FDA) to treat vulvovaginal candidiasis (VVC). Additionally, In November 2021, Profounda, Inc. a United States Bases company, received the Food and Drug Administration's Orphan Drug Designation Approval for the use of miltefosine to treat Invasive Candidiasis with Miltefosine. Thus, the recent developments in the United States is predicted to drive overall growth of the market studied in the region.

Therefore, owing to the previously mentioned factors the growth of the studied market is expected in the North America region.

#### Candidiasis Therapeutics Market Competitor Analysis

The candidiasis therapeutics market is competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are launching new products, while others are engaged in product developments and clinical trials. The competitive landscape includes an analysis of several companies which hold most of the market shares and are well known. Basilea Pharmaceutica Ltd., Astellas Pharma Inc., SCYNEXIS, Inc., Pacgen Life Science Corporation, NovaDigm Therapeutics, and Mycovia Pharmaceuticals, Inc., among others.

Additional Benefits:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- <ul> <li> The market estimate (ME) sheet in Excel format </li>

## **Table of Contents:**

### 1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

### 2 RESEARCH METHODOLOGY

### 3 EXECUTIVE SUMMARY

### 4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
  - 4.2.1 Increase in Number of Patients Affected by Candidiasis Infection
  - 4.2.2 Growing Awareness for Candidiasis Infection
- 4.3 Market Restraints
  - 4.3.1 Narrow Pipeline Molecules
  - 4.3.2 Competition from Herbal Medicines and Alternate Therapies
- 4.4 Porter's Five Forces Analysis
  - 4.4.1 Threat of New Entrants
  - 4.4.2 Bargaining Power of Buyers/Consumers
  - 4.4.3 Bargaining Power of Suppliers
  - 4.4.4 Threat of Substitute Products
  - 4.4.5 Intensity of Competitive Rivalry

### 5 MARKET SEGMENTATION (Market Size by Value - USD million)

- 5.1 By Route of Administration
  - 5.1.1 Injection
  - 5.1.2 Ointment
  - 5.1.3 Oral
- 5.2 By Drug Type
  - 5.2.1 Polyene
  - 5.2.2 Azole
  - 5.2.3 Echinocandin
  - 5.2.4 Others
- 5.3 By Anatomy Type
  - 5.3.1 Oral Candidiasis
  - 5.3.2 Vulvovaginal Candidiasis
  - 5.3.3 Cutaneous Candidiasis
  - 5.3.4 Invasive Candidiasis
  - 5.3.5 Systemic Candidiasis
- 5.4 By End-user
  - 5.4.1 Hospitals and Clinics
  - 5.4.2 Retail Pharmacies
  - 5.4.3 Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5 Geography
  - 5.5.1 North America
    - 5.5.1.1 United States
    - 5.5.1.2 Canada
    - 5.5.1.3 Mexico
  - 5.5.2 Europe
    - 5.5.2.1 Germany
    - 5.5.2.2 United Kingdom
    - 5.5.2.3 France
    - 5.5.2.4 Italy
    - 5.5.2.5 Spain
    - 5.5.2.6 Rest of Europe
  - 5.5.3 Asia-Pacific
    - 5.5.3.1 China
    - 5.5.3.2 Japan
    - 5.5.3.3 India
    - 5.5.3.4 Australia
    - 5.5.3.5 South Korea
    - 5.5.3.6 Rest of Asia-Pacific
  - 5.5.4 Middle-East & Africa
    - 5.5.4.1 GCC
    - 5.5.4.2 South Africa
    - 5.5.4.3 Rest of Middle-East & Africa
  - 5.5.5 South America
    - 5.5.5.1 Brazil
    - 5.5.5.2 Argentina
    - 5.5.5.3 Rest of South America

## 6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
  - 6.1.1 Basilea Pharmaceutica Ltd.
  - 6.1.2 Astellas Pharma Inc.
  - 6.1.3 SCYNEXIS, Inc.
  - 6.1.4 Pacgen Life Science Corporation
  - 6.1.5 NovaDigm Therapeutics
  - 6.1.6 Mycovia Pharmaceuticals, Inc.
  - 6.1.7 Amplyx Pharmaceuticals Inc.
  - 6.1.8 Biomar Microbial Technologies
  - 6.1.9 Cidara Therapeutics Inc.
  - 6.1.10 Novabiotics Limited

## 7 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Candidiasis Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts  
(2023 - 2028)**

Market Report | 2023-01-23 | 115 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-01"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

